Wasatch Advisors LP Increases Stock Holdings in TransMedics Group, Inc. $TMDX

Wasatch Advisors LP increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 346,144 shares of the company’s stock after purchasing an additional 14,296 shares during the quarter. Wasatch Advisors LP’s holdings in TransMedics Group were worth $34,410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kensington Investment Counsel LLC purchased a new stake in shares of TransMedics Group in the third quarter valued at $1,926,000. Fieldview Capital Management LLC purchased a new position in shares of TransMedics Group during the 3rd quarter worth about $1,716,000. Citigroup Inc. boosted its stake in shares of TransMedics Group by 29.3% during the 3rd quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after purchasing an additional 17,414 shares during the period. Fred Alger Management LLC grew its holdings in TransMedics Group by 303.8% during the 3rd quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock valued at $16,913,000 after purchasing an additional 113,408 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new position in TransMedics Group during the 4th quarter valued at about $1,788,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. Stifel Nicolaus increased their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Canaccord Genuity Group reduced their price target on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $134.50.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Trading Down 12.0%

TMDX stock opened at $68.44 on Friday. The company has a market capitalization of $2.37 billion, a PE ratio of 15.55 and a beta of 1.91. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The firm’s 50-day moving average is $79.48 and its 200 day moving average is $110.46. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period last year, the firm earned $0.70 earnings per share. On average, research analysts anticipate that TransMedics Group, Inc. will post 1.98 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.